SAFIRA is designed to offer a simple method to inject regional anaesthetic agents. Credit: Medovate.

UK-based medical device start-up Medovate has obtained the exclusive licence to design, develop, manufacture and launch two complementary local anaesthesia products.

One of the products, Regional Anaesthesia Device (RADS), has been created in alliance with Leeds Teaching Hospitals NHS Trust. It is a portable device that requires only one operator.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Under the terms of the licensing agreements, Medovate will be responsible for the design and development, regulatory approval, and the clinical trial to market launch of the products.”

Medovate also secured rights to Safer Injection for Regional Anaesthesia (SAFIRA), which is being developed with the Queen Elizabeth Hospital, King’s Lynn, NHS Foundation Trust.

SAFIRA is designed to offer end-to-end safety via a simple and quick method to inject regional anaesthetic agents. It allows enhanced data monitoring by recording the whole procedure with specific readings on time, pressure and volume.

Both RADS and SAFIRA are intended to deliver regional blocks within safe pressure limits.

Under the terms of the licensing agreements, Medovate will be responsible for the design and development, regulatory approval, and the clinical trial to market launch of the products.

Medovate managing director Stuart Thomson said: “There are approximately six million regional block procedures carried out in the EU and US each year. Injection above the published safe pressure threshold can lead to serious nerve damage in up to 1% of cases and transient nerve damage in up to 5% cases, so this is a major problem.

“There are also broader repercussions including financial compensation claims, increased anaesthetist and care provider anxiety and importantly, a rise in patient re-admission. RADS and SAFIRA together can tackle all these problems and help ensure that complications from nerve damage finally become a thing of the past.”

Launched by Health Enterprise East (HEE) in February this year, Medovate focuses on the development and commercialisation of medical technologies.

The company aims to offer financial and technical support to med tech innovators within the NHS.